ESMO 2014: Crizotinib and Second-Generation ALK Inhibitors in NSCLC

Speaker: Alice Shaw

A.Shaw comments on two ESMO 2014 abstracts looking at the efficacy of crizotinib and the anti-tumour activity of alectinib in ALK-positive non-small-cell lung cancer, and opens the way for promising second-generation ALK inhibitors.

Discussion Points

  • What was the rationale for the studies on crizotinib and second-generation ALK inhinitors
  • What were the top line results
  • What are the implications for clinical practice
  • Where is further research warranted

Abstracts Discussed

Abstract 1224O - Anti-tumor activity of alectinib in crizotinib pre-treated ALK-rearranged NSCLC in JP28927 study

Abstract 1225O - Overall and intracranial (IC) efficacy results and time to symptom deterioration in PROFILE 1014: 1st-line crizotinib vs pemetrexed - platinum chemotherapy (PPC) in patients (pts) with advanced ALK-positice non-squamous non-small cell lung cancer (NSCLC)